Aaron Craig is the new Director of Quality Assurance at VitaCyte, effective January 8, 2024. Aaron has over 20 years of experience managing and leading Eli Lilly’s, CBRE Workplace Solutions’, and MilliporeSigma’s quality assurance departments. Aaron’s expertise reflects VitaCyte’s ongoing commitment to setting the highest standards for manufacturing collagenase and protease enzymes as ancillary materials or biotherapeutic agents. We are excited for what 2024 will bring.
Aaron is a well-versed leader with over twenty years of experience in technical and quality oversight of sterile injectable, OSD, fermented/synthetic DS and DPs as well as significant experience in third party operations, acquisitions, and business/quality contracts.
Prior to joining VitaCyte, Aaron was the Head of Quality Operations at MilliporeSigma, Indianapolis where he had responsibility for the quality organization that handled QA on the floor support, raw materials and inspections, batch release, and client facing quality for the production of sterile injectable DPs.
Prior to MilliporeSigma, Aaron was the Corporate Quality Director for CBRE Global Workplace Solutions Life Science division for five years. Aaron was responsible for all contractual agreement aspects (MSA, QA, SLA) for regulated GxP quality and/or quality of service for large scope accounts across the facilities management network of clients globally.
Prior to CBRE, Aaron spent fifteen years with Eli Lilly & Co.; five years with front line drug product manufacturing and ten years with contract manufacturing oversight and M&A. At Eli Lilly, Aaron served as a senior technical services representative to produce multiple intermediate chemistries, DS, and DPs, spanning products from both small molecule synthetics to large molecule fermentation processes. During his last decade with Eli Lilly, he held multiple positions in technical services, quality assurance, and business development and was part of the original external manufacturing organization that charted Eli Lilly and Elanco’s (Eli Lilly’s animal and veterinary health company) significant expansion into the CDMO space.